The molecular and cellular landscape of hypertrophic cardiomyopathy phenotypes: transition from obstructive to

Jude Taylor1, Sean Lal2, Filip Braet3,4

  • 1Centre for Healthy Futures, Torrens University Australia, Surry Hills, NSW, 2010, Australia.

Journal of Molecular Medicine (Berlin, Germany)
|January 8, 2025
PubMed

Insights

Hypertrophic cardiomyopathy (HCM) shows distinct molecular and cellular differences between obstructive and end-stage disease. Obstructive HCM involves enhanced contractile function, while end-stage HCM features extensive tissue remodeling.

Area of Science:

  • Cardiovascular Biology
  • Genomics
  • Translational Medicine

Background:

  • Hypertrophic cardiomyopathy (HCM) is a myocardial disorder presenting as obstructive or end-stage disease.
  • Understanding the molecular transition between HCM phenotypes is crucial for targeted therapies.

Purpose of the Study:

  • To investigate transcriptomic and cell-specific expression profiles in obstructive and end-stage HCM.
  • To identify molecular signatures and cellular contributions underlying HCM phenotypes.

Main Methods:

  • Bioinformatics meta-analysis of independent gene expression datasets.
  • Gene set enrichment analysis and cellular deconvolution.
  • Identification of cell lineage genes and meta-genes.

Main Results:

  • Obstructive HCM: enhanced muscle function, myocardial remodeling, impaired immunity; increased cardiomyocytes, decreased immune cells.
  • End-stage HCM: enriched matrix remodeling, altered metabolism/signaling; increased fibroblasts, smooth muscle cells.
  • Distinct molecular and cellular profiles characterize HCM phenotypes.

Conclusions:

  • HCM phenotypes exhibit unique molecular and cellular landscapes.
  • Obstructive HCM is linked to enhanced contractile profiles and cardiomyocyte expansion.
  • End-stage HCM is characterized by extracellular matrix and vascular remodeling.